BioCentury
ARTICLE | Company News

Harmony crosses finish line with Wakix for narcolepsy

August 15, 2019 8:57 PM UTC

FDA approved Wakix pitolisant Thursday, almost two years after Harmony gained U.S. rights to the narcolepsy drug. During 2017-18, Harmony raised $295 million to push it through registration.

In October 2017, Harmony Biosciences LLC (Plymouth Meeting, Pa.) licensed exclusive U.S. rights to develop and commercialize Wakix from Bioprojet SCR (Paris, France), which markets the drug in the EU. The U.S. biotech also raised a $270 million equity round from investors including Valor Equity Partners; a $25 million financing from Aisling Capital and Soros Fund Management followed (see "Harmony Raises $270M")...

BCIQ Target Profiles

Histamine H3 receptor (HRH3)